- Home
- CTNT vs GLMD Comparison
CTNT vs GLMD Comparison
Compare CTNT & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNT | GLMD |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.4M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTNT | GLMD |
|---|---|---|
| Price | $1.16 | $0.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 85.2K | 63.7K |
| Earning Date | 11-07-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,420,060.00 | N/A |
| Revenue This Year | $235.67 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.66 |
| 52 Week High | $2.37 | $3.50 |
Technical Indicators
Market Signals| Indicator | CTNT | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 30.25 |
| Support Level | $1.09 | $0.66 |
| Resistance Level | $1.18 | $0.87 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 43.33 | 4.70 |
Price Performance
Historical ComparisonAbout CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a one-stop services including Warehousing, Logistics, International trading & Supply Chain Finance, Etc. It operate in single segment Logistics and warehousing services which focuses on providing freight forwarding services for clients shipping goods from the U.S. to mainland China or Hong Kong. Its services include: (i) cargo storage, (ii) freight forwarding, (iii) U.S. customs clearance, and (iv) labor services and cargo loading and unloading.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.